Donal J. Brennan

TL;DR: Blockade of pathways mediating macrophage recruitment, in combination with chemotherapy, significantly decreases primary tumor progression, reduces metastasis, and improves survival by CD8+ T-cell-dependent mechanisms, thus indicating that the immune microenvironment of tumors can be reprogrammed to instead foster antitumor immunity and improve response to cytotoxic therapy.

TL;DR: These findings show how targeting TAMs can effectively overcome therapeutic resistance mediated by TICs and improve chemotherapeutic efficacy, inhibits metastasis, and increases antitumor T-cell responses.

TL;DR: In this paper, the authors investigated whether inhibition of IL-6 has therapeutic activity in ovarian cancer via abrogation of a tumor-promoting cytokine network, and they combined pre-clinical and in silico experiments with a phase II clinical trial of the anti-IL-6 antibody siltuximab in patients with platinum-resistant ovarian cancer.

TL;DR: Emerging data suggests that measurement of survivin can aid the early diagnosis of bladder cancer, determine prognosis in multiple cancer types and predict response to diverse anti-cancer therapies.

TL;DR: The prognostic significance of stromal PDGF beta-receptor expression was particularly prominent in tumors from premenopausal women and should be considered in ongoing clinical development of PDGF receptor inhibitors.